Galapagos CEO Henry Gosebruch says the recent uptick in M&A activity is a positive development for the biotech as it pursues ...

“This change is deeply troubling because it is false and lacks transparency. There is no scientific rationale for CDC to ...

Though CMC barriers remain, strategic planning in the early development stages can guide a CGT product to success, noted ...

Aspen Neuroscience has closed a Series C funding round, raising $115m for the clinical development of its cell therapy ...

Alvotech and Advanz Pharma have announced EC marketing authorisations for Gobivaz, a biosimilar to Simponi, across the EEA.

Innovative linkers, connecting antibodies to payloads, are fine-tuning ADC selectivity while broadening their therapeutic ...

Moderna has announced the expansion of its US manufacturing capabilities with the onshoring of drug product manufacture to ...

Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

Novartis' two new sites in North Carolina fall under the Swiss pharma’s $23bn US manufacturing onshoring ploy.

Pfizer and Tris Pharma have agreed to pay $41.5m to settle allegations by the Texas Attorney General Ken Paxton ...

Mesenchymal stem cells have been explored across a wide range of diseases due to their potential to reduce inflammation and ...

Roche has conditional marketing authorisation from the EC for Lunsumio SC for adults with R/R FL after at least two systemic ...